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DiGeorge syndromeIn addition to causing polymalformative syndrome, 22q11.2 deletion can lead to various neuropsychiatric disor-
ders includingmental retardation, psychosis, and epilepsy. However, few reports regarding epilepsy-related psy-
chosis in 22q11.2 deletion syndrome (22q11.2DS) exist. We describe the clinical characteristics and course of
22q11.2DS in a Japanese patient with comorbid mild mental retardation, childhood-onset localization-related
epilepsy, and adult-onset, interictal schizophrenia-like psychosis. From a diagnostic viewpoint, early detection
of impaired intellectual functioning and hyperprolinemia in patients with epilepsywith 22q11.2DSmay be help-
ful in predicting the developmental timing of interictal psychosis. Froma therapeutic viewpoint, special attention
needs to be paid to phenytoin-induced hypocalcemia in this syndrome.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
22q11.2 deletion syndrome (22q11.2DS), also known asDiGeorge or
velocardiofacial syndrome, is one of the most common recurrent ge-
nomic disorder, with an estimated prevalence of 1 in 4000 live births
[1,2]. It results from a hemizygous microdeletion of approximately
1.5 to 3 Mb on the long arm of chromosome 22 [3]. Its phenotypic ex-
pression is highly variable and ranges from severe, life-threatening
conditions to only a few subtle features. Physical phenotypes include
cardiovascular malformations, palatal anomalies, immune deﬁciency,
hypocalcemia, hyperprolinemia, and dysmorphic facial features
[4]. Neuropsychiatric phenotypes include attention deﬁcit hyperac-
tivity disorder, autism spectrum disorders, schizophrenia, mood
disorders, anxiety disorders, intellectual disabilities, and epilepsy
[5]. Although psychosis and epilepsy may coexist in adult patients
with 22q11.2DS, few reports have discussed the clinical characteristics
of epilepsy-related psychosis in 22q11.2DS. Here, we report a case of
22q11.2DS in an adult patient with comorbid interictal schizophrenia-
like psychosis.llege, 3-2, Namiki, Saitama 359-
3.
.
. This is an open access article under2. Case report
A 40-year-old manwas admitted to our hospital for his ﬁrst episode
of psychosis, which occurred after a 2-month seizure-free period and
persisted for nearly 3 months.
The patient was born with polyhydramnios after an uncomplicated
full-term pregnancy. Tetralogy of Fallot was diagnosed at 8 months
and treated surgically at the age of 4 years. Other than a delay in
learning to walk on his own, no remarkable developmental delays
were mentioned during his preschool age. Unprovoked generalized
tonic–clonic seizures (GTCSs) during sleep appeared for the ﬁrst
time at the age of 13 years and subsequently occurred biweekly
without other seizure types. At the age of 14 years, the patient was
diagnosed with localization-related epilepsy and started on phenytoin
monotherapy. At the age of 20 years, his seizure frequency increased
in conjunctionwith new-onset hypocalcemia. At that time, hewas diag-
nosedwith idiopathic hypoparathyroidism. Following this diagnosis, he
maintained a combination therapy of phenytoin, phenobarbital, and
alfacalcidol. Through his 20s and 30s, he had only a few part-time jobs
and withdrew from social activities; however, his seizures were well
controlled, except when he forgot to take his medications. He had no
family history of epilepsy or psychiatric disorders.
At the time of admission, his height was 153 cm, and his weight was
56 kg. Hehad swollen eyelids, short palpebralﬁssures,ﬂat cheeks, a bul-
bous nose tip, a broad nasal root, and low-set ears. Physical examinationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
37Y. Tastuzawa et al. / Epilepsy & Behavior Case Reports 3 (2015) 36–38revealed clear consciousness, hypernasal speech, and a deviation of the
nasal septum. Neurological examination was unremarkable. A mental
status examination revealed a psychotic state including paranoid delu-
sions of being pursued, watched, and killed by someone. In addition,
the patient presented with auditory hallucinations of unfamiliar voices
commanding him to stab someone to death with a knife, intermittent
psychomotor excitement, and lack of insight. Neuropsychological
assessment revealed a full-scale IQ of 64, a verbal IQ of 71, and a perfor-
mance IQ of 61 on the Wechsler Adult Intelligence Scale, 3rd edition.
Blood count was normal without any sign of infection. Serum calcium
level was 8.8 mg/dL, and serum phosphorous level was 3.7 mg/dL. Thy-
roid function tests and intact parathyroid hormonewere normal. Serum
IgG, IgA, and IgM levels were normal. Amino acid analysis showed
severe hyperprolinemia (748.3 μmol/L). Serum phenytoin level was
12.5 μg/mL, and serum phenobarbital level was 14.8 μg/mL. Brain CT
and MRI scans showed bilateral basal ganglion calciﬁcation without
other cerebral malformations (Fig. 1). An ECG showed a complete
right bundle branch block. Interictal EEG showed high-voltage, bilateral
centroparietal 2- to 4-Hz spike-and-wave and sharp-and-wave com-
plexes, which were accentuated by hyperventilation (Fig. 2). The
22q11.2 deletion was conﬁrmed via a ﬂuorescence in situ hybridization
probe. To narrow down the breakpoints, single nucleotide polymor-
phism arrays were performed to reveal a deletion of about 2.5 Mb
(spanning the most commonly deleted region, presumably containing
10 pathogenic genes between PRODH and LZTR1).
Based on these ﬁndings, the patient was diagnosed as having
22q11.2DS, localization-related epilepsy, mild mental retardation, and
interictal schizophrenia-like psychosis. Risperidone (3 mg daily) was
effective against his psychotic symptoms and was well tolerated. After
his psychotic symptoms were alleviated, his phenytoin (200 mg po
daily) was successfully switched to levetiracetam (1000 mg po daily)
without seizure relapse. He was discharged from the hospital after
remaining seizure-free on the 81st day after the hospital admission.
3. Discussion
This is the ﬁrst case report to our knowledge to demonstrate the
clinical characteristics of 22q11.2DS in a patient with trimorbidity:
mild mental retardation, childhood-onset localization-related epilepsy,
and adult-onset interictal schizophrenia-like psychosis.
Hypocalcemic seizures and epilepsy have been associated with
22q11.2DS [6]. Although hypocalcemic seizures should be distinguished
from unprovoked seizures, the clinical manifestations of phenytoin-
induced hypocalcemia in patients with epilepsy with 22q11.2DS can
be indistinguishable from those of preexisting GTCSs, making diagnosis
difﬁcult. Phenytoin increases the metabolism of vitamin D and its
active metabolites by hepatic enzyme induction, which lowers calcium
absorption from the gut and causes hypocalcemia [7]. If a hypocalcemic
seizure occurs during phenytoin therapy, an increase in phenytoin doseFig. 1. Brain CT (left) and MRI (right) scans showed bilateral basal ganglion calciﬁcation
without other cerebral malformations.results in a paradoxical increase in seizure frequency. Indeed, our
patient's experience of a sudden reduction in seizure control at the
age of 20 years could be explained by phenytoin-induced hypocalcemia.
Because it can be paradoxically epileptogenic in the presence of hypo-
calcemia, phenytoin should be avoided or used carefully in patients
with 22q11.2DS.
Two cross-sectional studies have focused on the comorbidity
of psychosis and epilepsy associated with 22q11.2DS [8,9]. Raux et al.
investigated the genotype–phenotype correlations in 8 children
with type I hyperprolinemia and 92 adults or adolescents with
22q11.2DS [8]. The authors found an inverse correlation between
plasma proline levels and IQ scores and revealed that severe
hyperprolinemia (N550 μmol/L) was associatedwithmental retarda-
tion, psychotic disorder, and epilepsy. In addition, they suggested
that patients with hyperprolinemia with 22q11.2DS bearing the
Met-COMT low-activity allele had a high risk of psychosis. Although
there was no description of epilepsy classiﬁcation in this study,
their published data demonstrated that the group with epilepsy
with 22q11.2DS had a signiﬁcantly higher rate of comorbid psychotic
disorder (as deﬁned in the DSM-III-R) compared with the group
without epilepsy with 22q11.2DS (18.5% versus 4.6%). Sporn et al.
compared the clinical variables among 75 patients with childhood-
onset schizophrenia (COS) and 870 patients with adult-onset schizo-
phrenia (AOS) [9]. The authors found that patients with COS had a
signiﬁcantly higher prevalence of 22q11.2DS compared with pa-
tients with AOS (5.3% versus 0.46%) and that 75% of the patients
with COS with 22q11.2DS developed epilepsy. The results from the
two studies support the close relationship between epilepsy and
psychosis in the population with 22q11.2DS.
Our patient showed a 27-year-interval between the onset of epilep-
sy and that of the ﬁrst psychotic episode. Adachi et al. reported that the
mean interval between the onset of epilepsy and that of psychosis was
14.4 years; the authors also suggested that mental retardation and
localization-related epilepsy were considered risk factors for late-
onset interictal psychosis [10]. Applying this relationship to our case, it
is possible to consider that the comorbidity of mild mental retardation
and localization-related epilepsy may have contributed to the develop-
ment of middle-age-onset interictal psychosis in our patient. If so, early
detection of impaired intellectual functioning, as well as
hyperprolinemia, in patients with epilepsy with 22q11.2DS may be
helpful in predicting the developmental timing of interictal
psychosis.
The effectiveness and safety of antipsychotics in the treatment of
psychosis associated with 22q11.2DS (22q11.2DS-P) are not well
established. 22q11.2DS-P is relatively unresponsive to currently
used antipsychotic drugs [11]. Müller and Fellgiebel reported that
22q11.2DS-P in a 41-year-old female patient with a congenital
heart defect was successfully treated with quetiapine [12]. Carandang
and Scholten reported that aripiprazole-resistant 22q11.2DS-P was
successfully treated with metyrosine in a 17-year-old female patient
with a congenital heart defect and low COMT activity [13]. Several
researchers also reported that clozapine was effective against
22q11.2DS-P but increased the risk of provoked seizures [14,15]. Our
patient's 22q11.2DS-P symptoms improved on a low dose of risperi-
done, after failing to respond to quetiapine. When choosing an antipsy-
chotic drug, it is important to assess the associated risk of worsening
comorbid conditions and lowering the patient's quality of life.
4. Conclusions
In summary, a patient with hyperprolinemia with 22q11.2DS devel-
oped mild mental retardation, childhood-onset localization-related
epilepsy, and adult-onset interictal schizophrenia-like psychosis. From
a diagnostic viewpoint, early detection of impaired intellectual func-
tioning and hyperprolinemia in patients with epilepsy with 22q11.2DS
may be helpful in predicting the developmental timing of interictal
Fig. 2. Interictal EEG showed high-voltage, bilateral centroparietal 2- to 4-Hz spike-and-wave and sharp-and-wave complexes, which were accentuated by hyperventilation.
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